| openAccess | | 10-ene-2023 | Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Trøseid, Marius; Arribas, José Ramón; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzić, Vida; Mazzaferri, Fulvia; Rodríguez-Baño, Jesús CSIC ORCID; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, Jose‑Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale D. J. H.; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel, Martin; Ader, Florence; Lacombe, Karine; Amdal, Cecilie Delphin; Rodrigues, Serge; Tonby, Kristian; Gaudet, Alexandre; Heggelund, Lars; Mootien, Joy; Johannessen, Asgeir; Møller, Jannicke Horjen; Díaz-Pollán, Beatriz; Tveita, Anders Aune; Kildal, Anders Benjamin; Richard, Jean-Christophe; Dalgard, Olav; Simensen, Victoria Charlotte; Baldé, Aliou; Gastines, Lucie de; Álamo, Marta del; Aydin, Burç; Lund-Johansen, Fridtjof; Trabaud, Mary-Anne; Diallo, Alpha; Halvorsen, Bente; Røttingen, John-Arne; Tacconelli, Evelina; Yazdanpanah, Yazdan; Olsen, Inge C.; Costagliola, Dominique; EU SolidAct study group | artículo |
